1Siegel R,Naishadham D,Jemal A. Cancer statistics,2013[J].CA-A Cancer Journal for Clinicians,2013,(01):11-30.
2Karumanchi S A,Merchan J,Sukhatme V P. Renal cancer.molecular mechanisms and newer therapeutic options[J].Current Opinion in Nephrology and Hypertension,2002,(01):37-42.doi:10.1097/00041552-200201000-00006.
3Escudier B,Goupil M G,Massard C. Sequential therapy in renal cell carcinoma[J].CANCER,2009,(10):2321-2326.
4Escudier B,Eisen T,Stadler W M. Sorafenib in advanced clear-cell renal-cell carcinoma[J].New England Journal of Medicine,2007,(02):125-134.
5Fujii S,Ochiai A. Enhancer of zeste homolog 2 downre-gulates E-cadherin by mediating histone H3 methylation in gastric cancer cells[J].CANCER SCIENCE,2008,(04):738-746.doi:10.1111/j.1349-7006.2008.00743.x.
6Varambally S,Dhanasekaran S M,Zhou M. The polycomb group protein EZH2 is involved in progression of prostate cancer[J].NATURE,2002,(6907):624-629.
7Yu J,Yu J,Rhodes D R. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome[J].CANCER RESEARCH,2007,(22):10657-10663.
8Bachmann I M,Halvorsen O J,Collett K. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium,prostate,and breast[J].Journal of Clinical Oncology,2006,(02):268-273.
9Hu T,Guo H,Wang W. Loss of p57 expression and RhoA overexpression are associated with poor survival of patients with hepatocellular carcinoma[J].Oncology Reports,2013,(04):1707-1714.
10Yang X,Karuturi R K M,Sun F. CDKN1C (p57) is a direct target of EZH2 and suppressed by multiple epigenetic mechanisms in breast cancer cells[J].PLoS One,2009,(04):e5011.
